About Fore Biotherapeutics
Fore Biotherapeutics is a company based in Philadelphia (United States) founded in 2011. It operates as a HealthTech. Fore Biotherapeutics has raised $119 million across 3 funding rounds from investors including Orbimed, Samsung Securities and HBM Healthcare Investments. Fore Biotherapeutics offers products and services including Plixorafenib. Fore Biotherapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Philadelphia, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Fore Biotherapeutics Us Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$119 M (USD)
in 3 rounds
-
Latest Funding Round
$38 M (USD), Series D
Apr 30, 2025
-
Investors
Orbimed
& 12 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Fore Biotherapeutics
Fore Biotherapeutics offers a comprehensive portfolio of products and services, including Plixorafenib. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Plixorafenib is developed as a BRAF inhibitor for cancer.
Unlock access to complete
Unlock access to complete
Funding Insights of Fore Biotherapeutics
Fore Biotherapeutics has successfully raised a total of $119M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $38 million completed in April 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series D — $38.0M
-
First Round
First Round
(30 Apr 2018)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2025 | Amount | Series D - Fore Biotherapeutics | Valuation |
investors |
|
| Aug, 2023 | Amount | Series D - Fore Biotherapeutics | Valuation | SR One , Medicxi | |
| Apr, 2018 | Amount | Series A - Fore Biotherapeutics | Valuation | Bio Capital Impact Fund , Windham Venture Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Fore Biotherapeutics
Fore Biotherapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Samsung Securities and HBM Healthcare Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A biotechnology venture capital firm investing in innovative science.
|
Founded Year | Domain | Location | |
|
Early-stage life science focused VC firm investing in geographies such as Europe and the US
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Fore Biotherapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Fore Biotherapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Fore Biotherapeutics Comparisons
Competitors of Fore Biotherapeutics
Fore Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Fore Biotherapeutics
Frequently Asked Questions about Fore Biotherapeutics
When was Fore Biotherapeutics founded?
Fore Biotherapeutics was founded in 2011 and raised its 1st funding round 7 years after it was founded.
Where is Fore Biotherapeutics located?
Fore Biotherapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Is Fore Biotherapeutics a funded company?
Fore Biotherapeutics is a funded company, having raised a total of $119M across 3 funding rounds to date. The company's 1st funding round was a Series A of $6M, raised on Apr 30, 2018.
What does Fore Biotherapeutics do?
Fore Biotherapeutics is engaged in developing precision oncology treatments targeting patients with unaddressed tumor mutations. The company is involved in the healthcare sector, specifically biotechnology, with a focus on innovative therapies for hard-to-treat cancers. Their lead program, Plixorafenib, is designed as a next-generation BRAF inhibitor to address a wide range of BRAF gene alterations. Solutions are provided through clinical trials and strategic partnerships to deliver high-impact therapies with speed and quality.
Who are the top competitors of Fore Biotherapeutics?
Fore Biotherapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Fore Biotherapeutics offer?
Fore Biotherapeutics offers Plixorafenib.
Who are Fore Biotherapeutics's investors?
Fore Biotherapeutics has 13 investors. Key investors include Orbimed, Samsung Securities, HBM Healthcare Investments, SR One, and Medicxi.